We are a leading healthcare campus encompassing all fields of health: from healthcare and research to teaching and management.
Professionalism, commitment and research by professionals on the Campus are the key elements in offering patients excellent care.
We are committed to research as a tool to provide solutions to the daily challenges we face in the field of medical healthcare.
Thanks to our healthcare, teaching and research potential, we work to incorporate new knowledge to generate value for patients, professionals and the organization itself.
We generate, transform and transmit knowledge in all areas of the health sciences, helping to train the professionals of the future.
We are defined by our vocation for communication. We invite you to share everything that happens at Vall d'Hebron Barcelona Hospital Campus, and our doors are always open.
Hospital donations
Research donations
Currently, in the absence of scientific evidence, a withdrawal of ACEis or ARBs is not recommended in hypertensive patients.
Dr Maria José Soler, nephrologist at the Nephrology Service of the Vall d'Hebron University Hospital and member of the NephJC group. The Coronavirus Conundrum: ACE2 and Hypertention edition has participated in the position statement on the use of antihypertensive drugs such as ACEis or ARBs in patients infected with the SARS-CoV-2 virus and with hypertension prepared by the group. The document, which has been published in the kidney News Online journal of the American Society of Nephrology, recommends not stopping ACEIs or ARBs treatment in patients with confirmed COVID-19.
Angiotensin-converting enzyme inhibitors (ACEis) and angiotensin receptor antagonists (ARBs) are common treatments for high blood pressure.
Several organizations (American College of Physicians, the European Society of Cardiology, Hypertension Canada, the Canadian Cardiovascular Society, UK Renal Association, and the International Society of Hypertension, among others) have released statements corroborating this approach.
The current pandemic associated with the SARS-CoV-2 virus and COVID-19 disease is unprecedented, and healthcare professionals face many challenges, including whether the combination of drugs for chronic diseases influences the severity of the patient with coronavirus.
In this sense, aware of this concern, doctors and researchers, among whom is Dr. Soler, who is also a principal investigator of the Nephrology group of the Vall d'Hebron Research Institute (VHIR), have prepared a consensus document on role of preliminary reports and articles that have appeared in different magazines on the role of angiotensin converting enzyme (ACE) inhibitors and angiotensin receptor antagonists (ARBs) in the regulation of the expression of the gene of the angiotensin-converting enzyme 2 (ACE2). Several publications have pointed out that ACEis and ARBs agents could increase the regulation of ACE2 and, therefore, improve or facilitate the entry of SARS-CoV-2 into cells. Because the SARS-CoV-2 virus utilizes components of the renin angiotensin system (RAS) (ACE2 and TMPRSS2) to enter cells, it seemed plausible that ACEis and ARBs might exacerbate or even mitigate COVID-19.
Dr. Soler believes that "currently, in the absence of scientific evidence, a withdrawal of ACEis or ARBs is not recommended in hypertensive patients". "However, in patients with confirmed COVID-19 and who are receiving ACEi/ARB agents, , decisions on continuing or stopping these drugs should be done on an individualized basis by the treating physician", he points out.
This document will be updated based on new preclinical and clinical evidence, highly necessary at present.
By accepting these conditions, you are agreeing to the processing of your personal data for the provision of the services requested through this portal, and, if necessary, for any procedures required by the administrations or public bodies involved in this processing, and their subsequent inclusion in the aforementioned automated file. You may exercise your rights to access, rectification, cancellation or opposition by writing to web@vallhebron.cat, clearly stating the subject as "Exercising of Data Protection Rights". Operated by: Vall d’Hebron University Hospital Foundation – Research Institute. Purpose: Manage the user’s contact information. Legitimisation: Express acceptance of the privacy policy. Rights: To access, rectify, and delete personal information data, as well to the portability thereof and to limit and/or oppose their use. Source: The interested party themselves.